Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Posoleucel - Kalaris Therapeutics

Next Previous
Drug Profile

Posoleucel - Kalaris Therapeutics

Alternative Names: ALVR-105; Multivirus-specific T cell therapy - Kalaris Therapeutics; Viralym-M

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Baylor College of Medicine; Kalaris Therapeutics
  • Class Antivirals; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenovirus infections; Polyomavirus infections; Epstein-Barr virus infections; Cystitis; Cytomegalovirus infections; Human herpesvirus 6 infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Adenovirus infections; Cystitis; Cytomegalovirus infections; Epstein-Barr virus infections; Human herpesvirus 6 infections; Polyomavirus infections

Most Recent Events

  • 18 Mar 2025 AlloVir has merged with Kalaris Therapeutics to form Kalaris Therapeutics
  • 01 Feb 2024 AlloVir terminates a phase III trial in Cystitis (In infants, In children, In adolescents, In adults, In the elderly) in the US, France, Italy, South Korea, Spain, UK and Sweden (IV, Infusion), since the DSMB determined it was futile. No safety concerns were noted (NCT04390113) (EudraCT2020-000722-26)
  • 31 Jan 2024 AlloVir terminates phase III trial in Human herpesvirus 6 infections, Epstein-Barr virus infections, Adenovirus infections, Cytomegalovirus infections, Polyomavirus infections (In adolescents, In adults, In children, In infants, In the elderly, Prevention) in the US, South Korea, France, Italy, Spain, in the UK, Australia, Belgium, Canada, Turkey due to no safety concerns were noted (NCT05305040)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top